Chapter 5: Pricing and Reimbursement Issues in Neurology

Pricing and reimbursement issues in neurology Neurological disorders are common and highly disabling conditions that will impose a growing burden on aging societies in industrialized nations. We estimate that, in the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan alone, the number of people afflicted with Alzheimer's disease, epilepsy, multiple sclerosis, and Parkinson's disease will increase from approximately 15 million in 2005 to 17 million in 2015. Spending on drug therapies for these four disorders will grow even faster, increasing from $11 billion in 2005 to $18 billion in 2015. The size of this market is attributable in part to high drug prices, especially in the United States. The rising cost of routine poly-therapy and long-term use of these drugs has prompted payers to impose increasingly stringent cost-containment measures (e.g., price controls, prescribing budgets, formulary restrictions, increased cost-sharing). To secure favorable pricing and reimbursement terms in the ...

Users without subscription are not able to see the full content on this title. Please, subscribe or login to access all content on this website.

• Buy The Book